<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544152</url>
  </required_header>
  <id_info>
    <org_study_id>SCMP-0211-201</org_study_id>
    <nct_id>NCT02544152</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Lubiprostone in Adult Subjects With Mixed or Unsubtyped Irritable Bowel Syndrome (IBS-M/IBS-U)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sucampo AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sucampo Pharma Americas, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sucampo Pharma Americas, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of the efficacy and safety of Lubiprostone in subjects diagnosed with IBS-M/IBS-U.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the efficacy and safety of oral lubiprostone, as compared to matching placebo, when
      administered orally (at 8 mcg twice daily [BID]) in subjects diagnosed with IBS-M/IBS-U.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall abdominal pain response</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>A subject who qualifies as a weekly abdominal pain responder for at least 75% of observed treatment weeks. A weekly abdominal pain responder is defined as a subject reporting ≥30% reduction from baseline in average of 24-hour worst abdominal pain scores for that week using the 0-10 numeric rating scale (NRS) of pain intensity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall assessment of the proportion of subjects reporting ≥50% reduction from baseline in percentage of days with extreme stool consistency (Bristol Stool Form Scale ratings of 1, 2, 6 or 7).</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly assessment of the proportion of subjects reporting ≥50% reduction from baseline in percentage of days with extreme stool consistency (Bristol Stool Form Scale ratings of 1, 2, 6 or 7).</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly assessment of the proportion of subjects reporting ≥50% reduction from baseline in percentage of days with extreme stool consistency (Bristol Stool Form Scale ratings of 1, 2, 6 or 7).</measure>
    <time_frame>Month 1-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly assessment of abdominal pain response.</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>A weekly abdominal pain responder is defined as a subject reporting at least 30% reduction from baseline in average of 24-hour worst abdominal pain scores for that week using the 0-10 NRS of pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly assessment of abdominal pain response.</measure>
    <time_frame>Month 1-3</time_frame>
    <description>A monthly abdominal pain responder is defined as a subject who is a weekly abdominal pain responder for at least 2 of 4 weeks per month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall assessment of stool consistency response.</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>An overall stool consistency responder is defined as a subject who qualifies as a weekly stool consistency responder for at least 75% of observed treatment weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly assessment of stool consistency response.</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>A weekly stool consistency responder is defined as reporting at least 50% reduction from baseline in days with extreme stool consistency (Bristol Stool Form Scale ratings of 1, 2, 6 or 7) for a given week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly assessment of stool consistency response.</measure>
    <time_frame>Month 1-3</time_frame>
    <description>A monthly stool consistency responder is defined as a subject who is a weekly stool consistency responder for at least 2 of 4 weeks per month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mean change from baseline in abdominal pain</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>As a part of daily COA assessments, subjects will be asked to rate their abdominal pain in the past 24 hours. Scores range from 0 [no pain] to 10 [worst pain imaginable].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mean change from baseline in abdominal bloating</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>As a part of daily COA assessments, subjects will be asked to rate their abdominal bloating in the past 24 hours. Scores range from 0 [None], 1 [Mild], 2 [Moderate], 3 [Severe], 4 [Very Severe].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mean change from baseline in straining</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>As a part of daily COA assessments, subjects will be asked to rate their straining for each bowel movement reported. Scores range from 0 [None], 1 [Mild], 2 [Moderate], 3 [Severe], 4 [Very Severe].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mean change from baseline in stool consistency</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>As a part of daily COA assessments, subjects will be asked to rate their stool consistency for each bowel movement reported via the Bristol Stool Form Scale. Scores range from Type 1 [Separate hard lumps, like nuts (hard to pass)] to Type 7 [Watery, no solid pieces, Entirely Liquid].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mean change from baseline in improvement of most bothersome IBS symptom</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>Most bothersome IBS Sympton is collected from each subject as a part of Medical History during the screening period. For any symptom also collected as a part of the COA assessments (e.g. SBM frequency, straining, etc), changes from baseline will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean change from baseline in abdominal pain</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>As a part of daily COA assessments, subjects will be asked to rate their abdominal pain in the past 24 hours. Scores range from 0 [no pain] to 10 [worst pain imaginable]. Assessments will be separated into weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean change from baseline in abdominal bloating</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>As a part of daily COA assessments, subjects will be asked to rate their abdominal bloating in the past 24 hours. Scores range from 0 [None], 1 [Mild], 2 [Moderate], 3 [Severe], 4 [Very Severe]. Assessments will be separated into weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean change from baseline in straining</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>As a part of daily COA assessments, subjects will be asked to rate their straining for each bowel movement reported. Scores range from 0 [None], 1 [Mild], 2 [Moderate], 3 [Severe], 4 [Very Severe]. Assessments will be separated into weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean change from baseline stool consistency</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>As a part of daily COA assessments, subjects will be asked to rate their stool consistency for each bowel movement reported via the Bristol Stool Form Scale. Scores range from Type 1 [Separate hard lumps, like nuts (hard to pass)] to Type 7 [Watery, no solid pieces, Entirely Liquid]. Assessments will be separated into weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean change from baseline in improvement of most bothersome IBS symptom</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>Most bothersome IBS Sympton is collected from each subject as a part of Medical History during the screening period. For any symptom also collected as a part of the COA assessments (e.g. SBM frequency, straining, etc), changes from baseline will be calculated by week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly mean change from baseline in abdominal pain</measure>
    <time_frame>Month 1-3</time_frame>
    <description>As a part of daily COA assessments, subjects will be asked to rate their abdominal pain in the past 24 hours. Scores range from 0 [no pain] to 10 [worst pain imaginable]. Assessments will be separated into months (4-week period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly mean change from baseline in abdominal bloating</measure>
    <time_frame>Month 1-3</time_frame>
    <description>As a part of daily COA assessments, subjects will be asked to rate their abdominal bloating in the past 24 hours. Scores range from 0 [None], 1 [Mild], 2 [Moderate], 3 [Severe], 4 [Very Severe]. Assessments will be separated into months (4-week period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly mean change from baseline in straining</measure>
    <time_frame>Month 1-3</time_frame>
    <description>As a part of daily COA assessments, subjects will be asked to rate their straining for each bowel movement reported. Scores range from 0 [None], 1 [Mild], 2 [Moderate], 3 [Severe], 4 [Very Severe]. Assessments will be separated into months (4-week period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly mean change from baseline in stool consistency</measure>
    <time_frame>Month 1-3</time_frame>
    <description>As a part of daily COA assessments, subjects will be asked to rate their stool consistency for each bowel movement reported via the Bristol Stool Form Scale. Scores range from Type 1 [Separate hard lumps, like nuts (hard to pass)] to Type 7 [Watery, no solid pieces, Entirely Liquid]. Assessments will be separated into months (4-week period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly mean change from baseline in improvement of most bothersome IBS symptom</measure>
    <time_frame>Month 1-3</time_frame>
    <description>Most bothersome IBS Sympton is collected from each subject as a part of Medical History during the screening period. For any symptom also collected as a part of the COA assessments (e.g. SBM frequency, straining, etc), changes from baseline will be calculated by month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly global adequate relief questionnaire</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>&quot;Over the past week have you had adequate relief of your IBS symptoms?&quot; with binary &quot;Yes/No&quot; response asked weekly (every 7 days). Adequate relief of IBS symptoms is defined as a response of &quot;Yes&quot; to the question.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall health-related quality of life (IBS-QoL)</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall health-related status (EQ-5D)</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Lubiprostone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mcg capsules twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 mcg capsules twice daily (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone</intervention_name>
    <description>8 mcg administered orally twice daily (BID)</description>
    <arm_group_label>Lubiprostone</arm_group_label>
    <other_name>Amitiza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo, 0 mcg administered orally twice daily (BID)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject meets the diagnosis of IBS-M or IBS-U as confirmed using the adapted ROME III
             Diagnostic Questionnaire for Adult Functional GI Disorders.

          -  Subject Screening diary entries must show an average worst abdominal pain in the past
             24 hours score of at least 4 on a 11-point scale.

          -  Subject must be on a stable dose of selective serotonin re-uptake inhibitors (SSRIs),
             serotonin-specific reuptake inhibitor (SNRIs), or monoamine oxidase inhibitors (MAO)
             inhibitors if taking antidepressants.

        Exclusion Criteria:

          -  Subject has current diagnosis of IBS with diarrhea (IBS-D) or IBS with constipation
             (IBS-C), according to Rome III Criteria.

          -  Any gastrointestinal (GI) condition, other than IBS-related, affecting GI motility or
             defecation.

          -  Medical/surgical condition that might interfere with the absorption, distribution,
             metabolism, or excretion of the study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Barish, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Research Associates, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>E Squared Research, Inc.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Gastroenterology</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GW Research Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prestige Clinical Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Gastroenterology Associates, LLC</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meritus Center for Clinical Research</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates, LLC</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Endoscopy Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellness Clinical Research Associates</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research Associates</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

